BSF Trademark

Trademark Overview

On Tuesday, November 10, 2020, a trademark application was filed for BSF with the United States Patent and Trademark Office. The USPTO has given the BSF trademark a serial number of 90309535. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 5, 2024. This trademark is owned by Aquestive Therapeutics, Inc.. The BSF trademark is filed in the Pharmaceutical Products category with the following description:

Films dissolvable in the mouth for the oral delivery of drugs, pharmaceuticals and dietary supplements to humans; Dissolvable polymer films as a base in preparations for oral, sublingual, buccal, or transmucosal delivery of pharmaceutically active ingredients; Drug delivery platform technology, namely, drug delivery agents consisting of compounds that facilitate, enhance or promote optimized delivery, dosing management and accuracy, enhanced solubility, enhanced permeability, or enhanced absorption of a wide range of pharmaceutical agents; pharmaceutical preparations, namely, oral, sublingual, buccal, or transmucosal delivery enhancement agents to facilitate, enhance, or promote optimized delivery, dosing management and accuracy, enhanced solubility, enhanced permeability or enhanced absorption of a variety of pharmaceutical agents
bsf

General Information

Serial Number90309535
Word MarkBSF
Filing DateTuesday, November 10, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 4, 2021

Trademark Statements

Goods and ServicesFilms dissolvable in the mouth for the oral delivery of drugs, pharmaceuticals and dietary supplements to humans; Dissolvable polymer films as a base in preparations for oral, sublingual, buccal, or transmucosal delivery of pharmaceutically active ingredients; Drug delivery platform technology, namely, drug delivery agents consisting of compounds that facilitate, enhance or promote optimized delivery, dosing management and accuracy, enhanced solubility, enhanced permeability, or enhanced absorption of a wide range of pharmaceutical agents; pharmaceutical preparations, namely, oral, sublingual, buccal, or transmucosal delivery enhancement agents to facilitate, enhance, or promote optimized delivery, dosing management and accuracy, enhanced solubility, enhanced permeability or enhanced absorption of a variety of pharmaceutical agents

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, January 9, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAquestive Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWarren, NJ 07059
Party NameAquestive Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWarren, NJ 07059

Trademark Events

Event DateEvent Description
Friday, November 13, 2020NEW APPLICATION ENTERED
Saturday, January 9, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, March 15, 2021ASSIGNED TO EXAMINER
Friday, March 26, 2021EXAMINERS AMENDMENT -WRITTEN
Friday, March 26, 2021EXAMINERS AMENDMENT E-MAILED
Friday, March 26, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Friday, March 26, 2021EXAMINER'S AMENDMENT ENTERED
Friday, March 26, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, April 14, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 4, 2021PUBLISHED FOR OPPOSITION
Tuesday, May 4, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 29, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, December 23, 2021SOU TEAS EXTENSION RECEIVED
Thursday, December 23, 2021SOU EXTENSION 1 FILED
Thursday, December 23, 2021SOU EXTENSION 1 GRANTED
Saturday, December 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 15, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, June 15, 2022SOU EXTENSION 2 FILED
Wednesday, June 15, 2022SOU EXTENSION 2 GRANTED
Friday, June 17, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 25, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, August 25, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, August 25, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, August 25, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, December 14, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, December 14, 2022SOU EXTENSION 3 FILED
Wednesday, December 14, 2022SOU EXTENSION 3 GRANTED
Friday, December 16, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 30, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 30, 2023SOU EXTENSION 4 FILED
Tuesday, May 30, 2023SOU EXTENSION 4 GRANTED
Thursday, June 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 13, 2023SOU TEAS EXTENSION RECEIVED
Saturday, November 25, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, November 28, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sunday, July 28, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, November 13, 2023SOU EXTENSION 5 FILED
Saturday, November 25, 2023SOU EXTENSION 5 GRANTED
Sunday, July 28, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Sunday, July 28, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Sunday, July 28, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 5, 2024ABANDONMENT - NO USE STATEMENT FILED
Monday, August 5, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

delivery enhanced agents oral pharmaceutical drug facilitate management films accuracy